Details
Stereochemistry | RACEMIC |
Molecular Formula | C24H28N2O3 |
Molecular Weight | 392.4907 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=C(C=CC=C1)N2CCN(CC(O)COC3=CC=CC4=C3C=CC=C4)CC2
InChI
InChIKey=HRRBJVNMSRJFHQ-UHFFFAOYSA-N
InChI=1S/C24H28N2O3/c1-28-24-11-5-4-10-22(24)26-15-13-25(14-16-26)17-20(27)18-29-23-12-6-8-19-7-2-3-9-21(19)23/h2-12,20,27H,13-18H2,1H3
Molecular Formula | C24H28N2O3 |
Molecular Weight | 392.4907 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
DescriptionCurator's Comment: description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/23554846
http://www.ncbi.nlm.nih.gov/pubmed/19233432
Curator's Comment: description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/23554846
http://www.ncbi.nlm.nih.gov/pubmed/19233432
Naftopidil (INN, marketed under the brand name Flivas) is a drug used in benign prostatic hypertrophy which acts as a selective alpha1-adrenergic receptor antagonist, has been used for the treatment of benign prostatic obstruction and benign prostatic hyperplasia (BPH) associated lower urinary tract symptoms (LUTS). The Japanese Ministry of Health, Labor and Welfare approved naftopidil for treating men with BPH in 1996. Although well-designed, randomized studies are warranted to confirm the long-term outcomes and effector/target of naftopidil, the α1A-antagonist naftopidil, which also blocks α1D-adrenoceptor, improves voiding symptoms, and may also be useful for the management of men with storage symptoms represented by nocturia, retrieving their quality of life impaired by BPH-associated LUTS. The selective alpha1D-blocker naftopidil can significantly facilitate spontaneous passage of distal ureteral stones with few side effects, providing a new choice for medical expulsive therapy.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P35348|||B0ZBD9|||Q6RUJ8 Gene ID: 148.0 Gene Symbol: ADRA1A Target Organism: Homo sapiens (Human) Sources: http://www.ncbi.nlm.nih.gov/pubmed/10361884 |
3.7 nM [Ki] | ||
Target ID: P35368 Gene ID: 147.0 Gene Symbol: ADRA1B Target Organism: Homo sapiens (Human) Sources: http://www.ncbi.nlm.nih.gov/pubmed/10361884 |
20.0 nM [Ki] | ||
Target ID: P25100 Gene ID: 146.0 Gene Symbol: ADRA1D Target Organism: Homo sapiens (Human) Sources: http://www.ncbi.nlm.nih.gov/pubmed/10361884 |
1.2 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Secondary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Vascular alpha1-adrenoceptor subtype selectivity and alpha1-blocker-induced orthostatic hypotension. | 1998 May |
|
Direct determination of naftopidil by non-protected fluid room temperature phosphorescence. | 2001 Feb |
|
Determination of carvedilol in human cardiac tissue by high-performance liquid chromatography. | 2001 Mar |
|
Effects of intrathecal injection of tamsulosin and naftopidil, alpha-1A and -1D adrenergic receptor antagonists, on bladder activity in rats. | 2002 Aug 2 |
|
Flow injection chemiluminescence determination of naftopidil based on potassium permanganate oxidation in the presence of formaldehyde or formic acid. | 2005 Feb |
|
In vivo studies on the effects of alpha1-adrenoceptor antagonists on pupil diameter and urethral tone in rabbits. | 2006 Feb |
|
[Clinical application of alpha1 adrenoceptor antagonist Naftopidil to the treatment of chronic non-bacterial prostatitis]. | 2006 Mar |
|
[Effects of silodosin (KMD-3213) on phenylephrine-induced increase in intraurethral pressure and blood pressure in rats--study of the selectivity for lower urinary tract]. | 2006 Mar |
|
[Alpha1-adrenoceptor subtypes and alpha1-adrenoceptor antagonists]. | 2006 Mar |
|
Emerging drug therapies for benign prostatic hyperplasia. | 2006 Mar |
|
Ejaculatory disorder caused by alpha-1 adrenoceptor antagonists is not retrograde ejaculation but a loss of seminal emission. | 2006 Oct |
|
Crossover comparison study on the therapeutic effects of tamsulosin hydrochloride and naftopidil in lower urinary tract symptoms associated with benign prostatic hyperplasia. | 2007 Feb |
|
[Giant prostate carcinoma treated effectively with endocrine therapy: case report]. | 2007 Feb |
|
Change of expression levels of alpha1-adrenoceptor subtypes by administration of alpha1d-adrenoceptor-subtype-selective antagonist naftopidil in benign prostate hyperplasia patients. | 2007 Sep 1 |
|
Naftopidil, a selective alpha-1 adrenoceptor antagonist, inhibits growth of human prostate cancer cells by G1 cell cycle arrest. | 2008 Jan 15 |
|
[Effectiveness and safety of naftopidil for benign prostatic hyperplasia patients with overactive bladder symptoms]. | 2008 Oct |
|
Usefulness of naftopidil for dysuria in benign prostatic hyperplasia and its optimal dose--comparison between 75 and 50 mg. | 2009 |
|
[The clinical efficacy and safety of naftopidil 75 mg on benign prostatic hyperplasia patients with moderate or severe urinary disturbance]. | 2009 Apr |
|
Efficacy of selective alpha1D-blocker naftopidil as medical expulsive therapy for distal ureteral stones. | 2009 Apr |
|
Mechanical function and gene expression of alpha(1)-adrenoceptor subtypes in dog intravesical ureter. | 2009 Aug |
|
1,3-Dioxolane-based ligands as rigid analogues of naftopidil: structure-affinity/activity relationships at alpha1 and 5-HT1A receptors. | 2009 Mar |
|
The add-on effect of solifenacin for patients with remaining overactive bladder after treatment with tamsulosin for lower urinary tract symptoms suggestive of benign prostatic obstruction. | 2010 |
|
A prospective, randomized, controlled, multicenter study of naftopidil for treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia: 75 mg once daily in the evening compared to 25 mg thrice daily. | 2010 |
|
[Efficacy of naftopidil for nocturia and consequent sleep disturbance in patients with benign prostatic hyperplasia]. | 2010 Apr |
|
Functional alpha-1B adrenergic receptors on human epicardial coronary artery endothelial cells. | 2010 Dec |
|
Long-term treatment and prognostic factors of alpha 1-blockers for lower urinary tract symptoms associated with benign prostatic hyperplasia: a pilot study comparing naftopidil and tamsulosin hydrochloride. | 2010 Feb |
|
Clinical effect of naftopidil on the quality of life of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a prospective study. | 2010 Jun |
|
[A randomized controlled study comparing clinical effects of naftopidil and tamsulosin on benign prostatic hyperplasia]. | 2010 Sep |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/23554846
50 or 75 mg/day in Japanese men in clinical practice. For men in the US or European
countries, the optimal dose is estimated to be higher
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/17918159
Naftopidil has growth inhibitory effect in androgen-sensitive and -insensitive human prostate cancer cell lines. The concentrations causing 50% inhibition (IC50) of cancer cell growth were 22.2 +/- 4.0 microM in androgen-sensitive LNCaP cells and 33.2 +/- 1.1 microM in androgen-insensitive PC-3 cells.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:51:51 UTC 2023
by
admin
on
Fri Dec 15 15:51:51 UTC 2023
|
Record UNII |
R9PHW59SFN
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29713
Created by
admin on Fri Dec 15 15:51:51 UTC 2023 , Edited by admin on Fri Dec 15 15:51:51 UTC 2023
|
||
|
NCI_THESAURUS |
C1327
Created by
admin on Fri Dec 15 15:51:51 UTC 2023 , Edited by admin on Fri Dec 15 15:51:51 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
m7710
Created by
admin on Fri Dec 15 15:51:51 UTC 2023 , Edited by admin on Fri Dec 15 15:51:51 UTC 2023
|
PRIMARY | Merck Index | ||
|
100000091565
Created by
admin on Fri Dec 15 15:51:51 UTC 2023 , Edited by admin on Fri Dec 15 15:51:51 UTC 2023
|
PRIMARY | |||
|
DTXSID5045176
Created by
admin on Fri Dec 15 15:51:51 UTC 2023 , Edited by admin on Fri Dec 15 15:51:51 UTC 2023
|
PRIMARY | |||
|
5589
Created by
admin on Fri Dec 15 15:51:51 UTC 2023 , Edited by admin on Fri Dec 15 15:51:51 UTC 2023
|
PRIMARY | |||
|
C064357
Created by
admin on Fri Dec 15 15:51:51 UTC 2023 , Edited by admin on Fri Dec 15 15:51:51 UTC 2023
|
PRIMARY | |||
|
SUB09132MIG
Created by
admin on Fri Dec 15 15:51:51 UTC 2023 , Edited by admin on Fri Dec 15 15:51:51 UTC 2023
|
PRIMARY | |||
|
1873
Created by
admin on Fri Dec 15 15:51:51 UTC 2023 , Edited by admin on Fri Dec 15 15:51:51 UTC 2023
|
PRIMARY | |||
|
R9PHW59SFN
Created by
admin on Fri Dec 15 15:51:51 UTC 2023 , Edited by admin on Fri Dec 15 15:51:51 UTC 2023
|
PRIMARY | |||
|
DB12092
Created by
admin on Fri Dec 15 15:51:51 UTC 2023 , Edited by admin on Fri Dec 15 15:51:51 UTC 2023
|
PRIMARY | |||
|
NAFTOPIDIL
Created by
admin on Fri Dec 15 15:51:51 UTC 2023 , Edited by admin on Fri Dec 15 15:51:51 UTC 2023
|
PRIMARY | |||
|
57149-07-2
Created by
admin on Fri Dec 15 15:51:51 UTC 2023 , Edited by admin on Fri Dec 15 15:51:51 UTC 2023
|
PRIMARY | |||
|
C72927
Created by
admin on Fri Dec 15 15:51:51 UTC 2023 , Edited by admin on Fri Dec 15 15:51:51 UTC 2023
|
PRIMARY | |||
|
4418
Created by
admin on Fri Dec 15 15:51:51 UTC 2023 , Edited by admin on Fri Dec 15 15:51:51 UTC 2023
|
PRIMARY | |||
|
CHEMBL142635
Created by
admin on Fri Dec 15 15:51:51 UTC 2023 , Edited by admin on Fri Dec 15 15:51:51 UTC 2023
|
PRIMARY | |||
|
759293
Created by
admin on Fri Dec 15 15:51:51 UTC 2023 , Edited by admin on Fri Dec 15 15:51:51 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
Ki
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|